Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment
Marion A. J. van Rossum(Reade), Ben A. C. Dijkmans(Vrije Universiteit Amsterdam), Johanna C. M. Oostveen(Ziekenhuis Groep Twente), Maarten Boers(Amsterdam University Medical Centers), Nico Wulffraat(Utrecht University), R. ten Cate(Leiden University), R. M. van Soesbergen(Slotervaartziekenhuis), M. J. A. M. Franssen, W. Kuis(University Medical Center Utrecht), T. Fiselier(Boston Children's Hospital), Wilma H. J. van Luijk(University Medical Center Groningen), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), A. H. Zwinderman
Cited by 84
Related Papers
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome
|Nature Genetics|2000|951
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
|Annals of the Rheumatic Diseases|2016|331
Is a long‐term high‐intensity exercise program effective and safe in patients with rheumatoid arthritis?: Results of a randomized controlled trial
|Arthritis & Rheumatism|2003|299
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220